Protein-bound paclitaxel Press Release
|01/27/2020 - 22:01||
AVEO Oncology and Biodesix Announce Results from Phase 1b Study of Ficlatuzumab, Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer
The results were presented during a poster session at the 2020 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium. A copy of the presentation, titled “Phase 1b Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab in Patients with Advanced Pancreatic Cancer” (abstract 693), is available in the Publications & Presentations section of AVEO’s website.
|11/04/2019 - 07:34||
Halozyme Announces HALO-301 Phase 3 Study Fails To Meet Primary Endpoint
The treatment arm of PEGPH20 in combination with gemcitabine and nab-paclitaxel (ABRAXANE®) failed to demonstrate an improvement in median overall survival compared to gemcitabine and nab-paclitaxel alone (11.2 months compared to 11.5 months, HR=1.00, p=0.9692). While there was a higher response rate in the PEGPH20 treatment arm, this did not translate into an improvement in duration of response, Progression Free Survival or Overall Survival.
|10/31/2019 - 00:19||
DEP gemcitabine outperforms Gemzar in human pancreatic cancer model
Starpharma advances a new internal DEP® candidate, DEP® gemcitabine, into development DEP® gemcitabine demonstrated significantly enhanced anti-tumour activity compared with Gemzar® (gemcitabine), both alone and in combination with Nab‑paclitaxel (Abraxane®), in a human pancreatic cancer model Gemzar® (gemcitabine), used alone or in combination with Abraxane®, is the current standard of care therapy for pancreatic cancer A patent has been filed for Starpharma’s proprietary DEP® gemcitabine, providing coverage to 2040.
|10/30/2019 - 02:29||
Atlantic Health System Cancer Care Enrolling Patients in Innovative Pancreatic Cancer Clinical Trials
Atlantic Health System Cancer Care Enrolling Patients in Innovative Pancreatic Cancer Clinical Trials.
|10/03/2019 - 18:58||
Immunotherapy for triple negative breast cancer gets initial no for NHS in England
An immunotherapy treatment for triple negative breast cancer has been provisionally rejected for NHS use in England.
|Cancer Research UK|
|07/29/2019 - 18:20||
UA Researcher Explores New Treatment for Advanced Biliary Tract Cancers
Dr. Rachna Shroff is seeking a “goldmine of information” in her quest to extend survival and improve quality of life for patients with cancers of the liver, gallbladder and pancreas.
|03/11/2019 - 17:53||
FDA grants Roches Tecentriq in combination with Abraxane accelerated approval for people with PD-L1-positive, metastatic triple-negative breast cancer
This Tecentriq combination is the first cancer immunotherapy regimen approved for breast cancer Triple-negative breast cancer is an aggressive disease, with high unmet medical need.
|03/03/2019 - 21:40||
Rexahn Announces Target Enrollment Reached in Phase 2a Clinical Trial of RX-3117 in Combination With ABRAXANE in First-line Metastatic Pancreatic Cancer Patients
This multicenter, single-arm, open-label study is designed to evaluate the safety and efficacy of RX-3117 in combination with ABRAXANE in first-line metastatic pancreatic cancer patients. As of February 27, 2019, the target enrollment of 40 patients has been achieved. Patients were enrolled into the study from 10 centers in the US. The primary endpoint is progression free survival and study is expected to be completed in the second half of 2019.
|02/04/2019 - 00:07||
Rexahn Receives Notice of Allowance for U.S. Patent Covering RX-3117 Use in a Broad Range of Tumor Types
The company expects the patent to be issued within a few months from the notice of allowance and provide protection to 2036.
|01/22/2019 - 18:50||
Rexahn Presents Updated Preliminary Data on RX-3117 in Pancreatic Cancer at the 2019 ASCO GI Symposium
Overall Response Rate of 38% Observed in the First 24 Patients Who Had At Least One Scan on Treatment.
|01/22/2019 - 01:14||
Overall Response Rate of 38% Observed in the First 24 Patients Who Had At Least One Scan on Treatment
The multicenter, single-arm, open-label study is designed to evaluate RX-3117 in combination with ABRAXANE in first-line metastatic pancreatic cancer patients. The Phase 2a trial is expected to enroll 40 evaluable patients. As of January 9, 2019, 36 patients were enrolled into the study, and 24 patients had at least one scan on treatment and were included in the evaluation of overall response.
|11/26/2018 - 20:10||
Halozyme Announces Change In Primary Endpoint For HALO-301 To Overall Survival
As a result, the previously planned interim analysis will not be conducted. The company will host a webcast and conference call today at 5 p.m. Eastern / 2 p.m. Pacific to discuss this change in further detail.
|11/16/2018 - 07:17||
DEP docetaxel and DEP cabazitaxel outperform in human pancreatic cancer model
DEP® cabazitaxel, both alone and in combination with gemcitabine, showed complete tumour regression and 100% survival in a human pancreatic cancer model DEP® docetaxel alone significantly outperformed standard treatments gemcitabine and/or Abraxane® and achieved 100% survival DEP® docetaxel when combined with gemcitabine showed complete tumour regression and 100% survival in this model The complete tumour regression induced by both DEP® products was despite the fact that standard pancreatic cancer treatments, gemcitabine and Abraxane® alone and in combination showed lim
|11/13/2018 - 14:43||
FDA grants priority review to Roches Tecentriq in combination with Abraxane for the initial treatment of people with PD-L1-positive, metastatic triple-negative breast cancer
Triple-negative breast cancer is an aggressive disease, with high unmet medical need If approved, this Tecentriq (atezolizumab) combination would be the first cancer immunotherapy regimen for the treatment of PD-L1-positive, metastatic triple-negative breast cancer.
|10/22/2018 - 16:42||
First Results of New Data of ABRAXANE in Combination with Atezolizumab Presented at ESMO 2018
IMpower130 demonstrated significant overall survival (OS) and progression-free survival (PFS) benefit of ABRAXANE/carboplatin plus atezolizumab in advanced non-squamous non-small cell lung cancer (NSCLC) patients.
|10/21/2018 - 21:41||
Roches Tecentriq plus chemotherapy (carboplatin and Abraxane) as an initial treatment helped people with advanced non-squamous non-small cell lung cancer live significantly longer compared to chemotherapy alone
The Phase III IMpower130 study investigating the Tecentriq plus chemotherapy combination demonstrated a significant overall survival (OS) and progression-free survival (PFS) benefit Data will be presented at the European Society for Medical Oncology (ESMO) 2018 Congress on 22 October 2018.
|10/20/2018 - 10:44||
Komen Hails Findings from IMpassion130 Trial Showing New Treatment Option for Metastatic Triple Negative Breast Cancers
The findings are the first positive Phase III study of a cancer immunotherapy combination in breast cancer. It showed the combination of Roche’s immunotherapy drug Tecentriq® (atezolizumab) and the chemotherapy drug nab-paclitaxel used as a first-line treatment significantly reduced the risk of the disease worsening and improved survival in people with metastatic (stage IV) triple negative breast cancers that express the PD-L1 protein.
|Susan G Komen|
|10/19/2018 - 23:42||
Roches Tecentriq in combination with Abraxane improves outcomes as an initial treatment for people with PD-L1-positive metastatic triple-negative breast cancer
Tecentriq combination first immunotherapy regimen to demonstrate positive Phase III results in breast cancer Tecentriq and nab-paclitaxel significantly reduced the risk of disease worsening or death in both the intention-to-treat and PD-L1-positive populations Clinically meaningful overall survival improvement in the PD-L1-positive population at this interim analysis Data are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress, featured in the press programme and simultaneously published in the New England Journal of Medicine on 20 October 2018.
|10/19/2018 - 21:22||
Genentechs Tecentriq in Combination With Abraxane Improves Outcomes as an Initial Treatment for People With PD-L1-Positive Metastatic Triple-Negative Breast Cancer
Tecentriq combination first immunotherapy regimen to demonstrate positive Phase III results in breast cancer.
|10/02/2018 - 17:45||
Rexahn Pharmaceuticals Presents Preliminary Safety and Efficacy Data From Ongoing Phase 2a Clinical Trial of RX-3117 in Combination With Abraxane in Patients Newly Diagnosed With Metastatic Pancreatic Cancer
Combination of RX-3117 and Abraxane Appears Safe and Well-Tolerated When Administered at the Recommended Phase 2 Dose of RX-3117 and the Maximal Labeled Dose of Abraxane.
|10/01/2018 - 15:40||
Corcept Therapeutics Receives Orphan Designation for Relacorilant as Treatment for Pancreatic Cancer
Corcept is conducting clinical trials of relacorilant in combination with nab-paclitaxel (Celgene Corporation’s drug, Abraxane®) as a treatment for pancreatic cancer and other solid tumors.
|09/18/2018 - 19:06||
Rexahn Pharmaceuticals to Present at the 5th NCI Pancreatic Cancer Symposium
Preliminary Safety and Efficacy Data from the Ongoing Phase 2a Clinical Trial of RX-3117 in Combination with Abraxane® in Patients Newly Diagnosed with Metastatic Pancreatic Cancer will be presented.
|07/10/2018 - 12:25||
Anti-PD-L1 Immunotherapy Plus ABRAXANE Significantly Reduced the Risk of Disease Worsening or Death in Patients with Metastatic or Locally Advanced Triple Negative Breast Cancer in Phase III IMpassion130 Study
SUMMIT, N.J.--( )-- Celgene Corporation (NASDAQ:CELG) today announced that the Phase III IMpassion130 study, which was sponsored by Roche, met its co-primary endpoint of progression-free survival (PFS). This is the first phase III study to demonstrate a statistically significant PFS improvement in first-line metastatic or unresectable locally advanced triple negative breast cancer (TNBC), a type of breast cancer with high unmet need.
|07/02/2018 - 10:42||
Phase III IMpassion130 study showed Roches Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion130 study met its co-primary endpoint of progression-free survival (PFS). Results demonstrated that the combination of Tecentriq® (atezolizumab) plus chemotherapy (Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]), as an initial (first-line) treatment, significantly reduced the risk of disease worsening or death (PFS) in the intention-to treat and PD-L1 positive population with metastatic or unresectable locally advanced triple negative breast cancer (TNBC). Overall survival (OS) is encouraging in the PD-L1 positive population at this interim analysis, and follow up will continue until the next planned analysis.
|06/28/2018 - 11:30||
Atlantic Health System Enrolling Patients in Pancreatic Cancer Clinical Trials
All Pancreatic Cancer Studies Led by Nationally Known Expert, Dr.